Is Long-Acting Injectable Cabotegravir Likely to Expand PrEP Coverage Among MSM in the District of Columbia?

Authors

Matthew E. Levy, George Washington University
Anya Agopian, George Washington University
Manya Magnus, George Washington University
Anthony Rawls, George Washington University
Jenevieve Opoku
Michael Kharfen
Alan E. Greenberg, George Washington University
Irene Kuo, George Washington University

Document Type

Journal Article

Publication Date

3-1-2021

Journal

Journal of Acquired Immune Deficiency Syndromes

Volume

86

Issue

3

Inclusive Pages

e80-e82

DOI

10.1097/QAI.0000000000002557

APA Citation

Levy, M. E., Agopian, A., Magnus, M., Rawls, A., Opoku, J., Kharfen, M., Greenberg, A. E., & Kuo, I. (2021). Is Long-Acting Injectable Cabotegravir Likely to Expand PrEP Coverage Among MSM in the District of Columbia?. Journal of Acquired Immune Deficiency Syndromes, 86 (3). http://dx.doi.org/10.1097/QAI.0000000000002557

Peer Reviewed

1